Friday Factoids: Disruptive Mood Dysregulation Disorder

Disruptive mood dysregulation disorder (DMDD) is a newer diagnosis in childhood that is depicted by extreme irritability, anger, and frequent outbursts (National Institute of Mental Health [NIMH], 2016).  Irritability is a clinical symptom of both bipolar disorder and DMDD (Wiggins et al., 2016).  Comparatively, irritability in DMDD is “severe and relatively invariant over time,” yet irritability experienced with bipolar disorder may occur while a child is euthymic and may increase during manic or depressive episodes (Wiggins et al., 2016, p. 722). Thus the inclusion of DMDD in part allows for appropriate diagnosis for children with “severe, nonepisodic irritability” that is distinct from bipolar disorder (Wiggins et al., 2016, p. 722).

 

With DMDD being a new diagnosis, treatment is often based on other disorders with shared symptomatology (e.g., attention-deficit/hyperactivity disorder, anxiety disorders, oppositional defiant disorder, and major depression; NIMH, 2016). Cognitive-behavior therapy (CBT), parent training, and computer-based training are recommended psychological interventions (NIMH, 2016) for DMDD, where as medications may also be considered.  For instance, stimulants may help address irritability, antidepressants may mitigate irritability and mood problems, and atypical antipsychotics could be used to alleviate severe outbursts with physical aggression (NIMH, 2016).

 

The potential for adverse effects with some treatments limit their use in children, resulting in the necessity to explore noninvasive means for treatment (Wiggins et al., 2016).  For instance, the use of a video game to reduce the misinterpretation of ambiguous faces in children with irritability has shown to help reduce anger-based reactions found in DMDD.  The literature has shown that children with DMDD and bipolar disorder tend to rate neutral faces as angry (Wiggins et al., 2016). Research conducted by Wiggins et al. (2016) has demonstrated that a computer game helped to change the tendency to misinterpret ambiguous faces as angry in irritable children.  After training, children were more likely to rate ambiguous faces as happy (Wiggins et al., 2016).  Such an intervention may appear superficial, however this research has demonstrated that brain activation patterns when labeling emotional faces differs between DMDD and bipolar disorder (Wiggins et al., 2016).  Specifically, amygdala activation related to irritability differed between children with DMDD and bipolar disorder; and temporo-occipital regions of the brain had “associations between irritability and activation in response to ambiguous angry faces” (Wiggins et al., 2016, p. 728).

 

Thus, differing brain activation patterns helped distinguish the clinical presentation of DMDD versus bipolar disorder (Wiggins et al., 2016).  As a result, the authors conclude that though irritability is a common symptom of both DMDD and bipolar disorder, they are in fact distinct disorders and given the different neural correlates, treatments may also be different (Wiggins et al., 2016).

 

References
National Institute on Drug Abuse (NIDA). (2016). Disruptive Mood Dysregulation Disorder. Retrieved from http://www.nimh.nih.gov/health/topics/disruptive-mood-dysregulation-disorder-dmdd/disruptive-mood-dysregulation-disorder.shtml

 

Wiggins, J. L., Brotman, M. A., Adleman, N. E., Kin, K., Oakes, A. H. Reynolds, R. C.,…Leibenluft, E. (2016).  Neural correlates of irritability in disruptive mood dysregulation and bipolar disorders.  American Journal of Psychiatry, 173, 722-730.

 

 

Dannie S. Harris, MA
WKPIC Doctoral Intern

 

 

Massive WOOHOOs and CONGRATULATIONS!

WKPIC would like to extend giant happy dances to the following brilliant folks:

 

First, former intern and current post-doc Crystal Bray successfully defended her dissertation!

 

20160825-DSC_2098

 

 

 

 

 

 

20160901-DSC_2315Seconnd, current intern Dannie Harris passed the EPPP–at the doctoral level!

 

 

 

 

 

 

 

 

 

 

 

 

YOU LADIES ROCK!!!

 

Susan Redmond-Vaught, Ph.D.
Director, WKPIC

Friday Factoids: Methamphetamine Psychosis

 

As reported by the National Institute on Drug Abuse (NIDA; 2013) methamphetamine use continues to be a significant problem, with over 12 million people or 4.7 percent of the population having tried methamphetamine at least one time.  According to NIDA (2013), methamphetamine use can cause memory loss, aggression, psychotic behavior, damage to one’s cardiovascular system, malnutrition, and dental problems.

 

Chronic use may cause an individual to have difficulty feeling pleasure outside of use, as well as anxiety, confusion, insomnia, mood disturbance, and violent behavior. Psychotic features experienced include paranoia, delusions, and visual, auditory, and tactile hallucinations.  Stress has also been related to spontaneous methamphetamine psychosis in individuals who have abused methamphetamine in the past (NIDA, 2013).  With acute methamphetamine intoxication individuals may experience hallucinations (auditory, visual, tactile), persecutory, influence, and control delusions, as well as are prone to violence (Zarrabi, Khalkhali, Hamidi, Ahmadi, & Zavarmousavi, 2016).

 

Even after intoxication passes, psychosis may occur over a prolonged period of time (Zarrabi et al., 2016).  Acute psychosis usually has a maximum period of four to five days (Zarrabi et al., 2016); yet, a differing course of psychosis has been documented in the literature. For instance, three clinical groups for stimulant-induced psychosis have been identified:  the first group is characterized by transient psychosis, where the duration of symptoms is limited to four or five days and may be associated with withdrawal; with the second group, psychosis is typically resolved in less than one month; and in the third group, psychosis may last several months or years (Zarrabi et al., 2016).  It has been estimated that between 5-10% of individuals with methamphetamine-induce psychosis may not fully recover (as cited in Zarrabi et al., 2016).

 

Risk factors for methamphetamine-induced psychosis are duration, frequency, and amount of use, history of sexual abuse, family history, other substance use, and co-occurring personality and mood disorders (Grant et al., 2012). Of note, substance intoxication is differentiated from a substance/medication-induced psychotic disorder if reality testing for altered perceptions remains intact (American Psychiatric Association, 2013).

 

Zarrabi, Khalkhali, Hamidi, Ahmadi, and Zavarmousavi (2016) indicate there are no structured treatment guidelines for methamphetamine-induced psychosis.  In their study, risperidone and olazapine were most frequently used, as well as benzodiazepines to reduce restlessness. Antipsychotics were reportedly preferred due to better control of violent behaviors.  Another study indicated that quetiapine could also be used as an antipsychotic treatment with comparable effects to haloperidol (Verachai et al., 2014). Electroconvulsive therapy (ECT) has been used to control severe aggression and violent behaviors, as well as thoughts of suicide and homicide in methamphetamine-induced psychosis (Zarrabi et al., 2016).  Results indicated that after six to nine sessions of ECT, symptoms began to disappear.  Though limited by constraints of a case study, Grelotti, Kanayama, and Harrison (2010) again demonstrated the positive effects of ECT on methamphetamine-induced psychosis.

 

Overall, the most common symptoms with methamphetamine-induced psychosis are paranoid delusions and auditory hallucinations, and such symptoms may prove resistant or refractory to antipsychotic medications (Grelotti, Kanayama, & Pope, 2010).  As indicated in the literature, clinicians faced with refractory cases of methamphetamine-induced psychosis may consider ECT as a treatment option.

 

 

References
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.

 

Gerlotti, D., Kanayama, G., & Pope, H. G. (2010). Remission of persistent methamphetamine-induced psyhcosis after electroconvulsive therapy: Presentation of a case and review of literature. The American Journal of Psychiatry, 167(1), 17-23.

 

Grant, K. M., LeVan, T. D., Wells, S. M., Li, M., Stoltenberg, S. F., Gendelman, H. E.,…BEvins, R. A. (2012). Methamphetamine-associated psychosis. Journal of Neuroimmune Pharmacology, 7(1), 113-139.

 

National Institute on Drug Abuse (NIDA). (2013).  Methamphetamine. Retrieved from https://www.drugabuse.gov/publications/research-reports/methamphetamine

 

Verachai, V., Rukngan, W., Chaswanakrasaesin, K., Nilaban, S., Suwanmajo, S., Thanateerabunjong, R.,…Kalayasiri, R. (2014). Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine. Psychopharmacology, 231(16), 3099-3108.

 

Zarrabi, H., Khalkhali, M., Hamidi, A., Ahmadi, R., & Zavarmousavi, M. (2016). Clinical features, course and treatment of methpahetamine-induce psychosis in psychiatric inpatients. BMC Psychiatry, 16, 1-8.

 

Dannie S. Harris, MA
WKPIC Doctoral Intern

 

 

 

Friday Factoids: Motivational Interviewing as a Clinical Option for Generalized Anxiety Disorder

Cognitive-behavior therapy (CBT) has shown to be efficacious for treating anxiety, yet some clients “either fail to respond, respond only partially, or relapse at follow-up” (Westra, Constantino, & Antony, 2016, p. 768).  As reported by Hunot, Churchhill, Teixeria, and Silva de Lima (2007; as cited in Westra et al., 2016), only 46% of clients with Generalized Anxiety Disorder (GAD) demonstrated significant improvement after therapy.  One factor that may contribute to poorer outcomes is ambivalence.  Ambivalence in anxiety is holding positive beliefs about worry and being reluctant to change or let go of the worry (Westra & Arkowitz, 2010; as cited in Westra et al., 2016).  Additionally, therapeutic directness or demands related to change might be met with resistance (Westra et al., 2016).  Thus, additional components that work with ambivalence may boost treatment outcomes by working through resistance, all while remaining anchored in CBT.

 

Motivational Interviewing (MI) is a treatment with a focus on ambivalence (Miller & Rollnick, 2002).  Here the therapist is not the advocate for change, rather therapists assist clients to be their own advocate for change (Westra et al., 2016).   With specific strategies, MI helps reduce resistance and “increases intrinsic motivation” for change (Westra et al., 2016, p. 769).  In their study, Westra, Constantino, and Antony  (2016) investigated the effects of integrating MI and CBT for severe GAD.  In the study, one group received 15 weekly session of CBT alone (CBT-alone) and another group had 4 sessions of MI followed by 11 sessions of CBT integrated with MI (MI-CBT).  Initially, there were no posttreatment differences between groups; yet, at the 6- and 12-month follow-up, several group differences emerged. The MI-CBT group reported a continued improvement on self-reported worry and general distress after treatment ended.  MI-CBT clients also had significantly higher rates of recovery and clinically significant change (five times as likely to not meet diagnostic criteria for GAD).   Westra et al. (2016) indicated that similar sleeper-type effects are often reported with MI use in treating other disorders.

 

So, why did clients continue to improve after treatment?  Westra et al. (2016) indicated that the opportunity to explore ambivalence and becoming more committed to change might help clients not respond to worry, thus reducing relapse rates.  Additionally, the authors suggested that MI techniques fostered the development of personal agency, which may have led to the client’s belief that they are capable of change, resulting in internalization of this belief.  By “rolling with resistance” and viewing the “client-as-expert” helped to “promote internal attributions for progress” (Westra et al., 2016, p. 777).  With this model, the efficacy of CBT treatment for GAD is maintained, yet by integrating MI where clients can openly explore resistance may help clients become more receptive to traditional CBT techniques.

 

 

References
Miller, W. R., & Rollnick, S. (2002). Motivational interviewing: Preparing people for change (2nd ed.). New York, NY: Guilford Press.

 

Westra, H. A., Constantino, M. J., & Antony, M. M. (2016). Integrating motivational interviewing with cognitive-behavioral therapy for severe generalized anxiety disorder: An allegiance-controlled randomized clinical trial. Journal of Consulting and Clinical Psychology, 84(9), 768-782.

 

Dannie S. Harris, MA
WKPIC Doctoral Intern

Friday Factoids: Working With Children Who Have Early-Onset Schizophrenia

 

Though diagnostic criteria for early-onset schizophrenia are the same for adults and children, the treatment approach may differ. For instance, discussing the symptoms of psychosis with children can be challenging.  Often parental report is utilized when discussing symptoms; however, as noted by Caplan (2011), parents may be unaware of the experience of hallucinations by their child.

 

Children may not spontaneously talk about hallucinations due to others negating the experience (e.g., It’s nothing; It’s only your imagination), being scared to talk about it, feeling they will burden their parents with it, or believing that talking about the hallucination will make it happen (Caplan, 2011).  Clinicians should use careful wording to ask about hallucinations.  Delusions, like hallucinations, should be differentiated from normal developmental phenomena (e.g., fantasies, magical thinking; Caplan, 2011).  Though morbid fantasies may be upsetting, they too are common (Caplan, 2011); however, if they are pervasive and acted upon they might be “precursors of delusions” (Caplan, 2011, p. 60).  Disorganized speech and thought disorders are reflected in illogical thinking, loose associations, and impaired discourse skills (Caplan, 2011; Shatkin, 2015).  This communication difficulty must be distinguished from language problems related to language disorders or intellectual disability (Caplan, 2011; Stentebjerg-Olesen et al., 2016); thus it may be beneficial to refer to speech or language therapist to help clarify diagnoses.

 

Compared to adults, negative symptoms are more prominent in children and adolescents (Harvey, James, & Shields, 2016).  Additionally, negative symptoms are noted to be predictors of poorer clinical and functional outcomes (Harvey et al., 2016).  Other symptoms related to early-onset schizophrenia are abnormalities of gait, posture, and muscle tone (Shatkin, 2015).

 

Given the trajectory and progressive course of schizophrenia, early identification and intervention should be emphasized, especially in light of the findings that longer duration of untreated psychosis and poorer premorbid adjustment are associated with poorer outcomes  (Stentebjerg-Olesen, Pagsberg, Fink-Jensen, Correll, & Jeppesen, 2016).  Furthermore, early-onset schizophrenia is often refractory to treatment.  Recent research has indicated that clozapine demonstrated greater efficacy compared to other antipsychotics (Kasoff, Ahn, Gochman, Broadnax, & Rapoport, 2016), where as other research (Harvey et al., 2016) demonstrated that antipsychotics showed a trend of reduction of symptoms compared to placebos, but only olanzapine and risperidone demonstrated statistically significant improvements for positive symptoms, as well as general psychopathology as measured by the Positive and Negative Syndrome Scale (PANSS).

 

References
Caplan, R. (2011). Childhood schizophrenia: Diagnostic and treatment challenges. Cutting Edge Psychiatry in Practice, 3(1),  55-67.

 

Harvey, R. C., James, A. C., & Shields, G. E. (2016). Assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs, 30(1), 27-39.

 

Kasoff, L. I., Ahn, K., Gochman, P., Broadnax, D. D., & Rapoport, J. L. (2016). Strong treatment response and high maintenance rates of clozapine in childhood-onset schizophrenia. Journal of Child and Adolescent Psychopharmacology, 26(5), 428-435.

 

Shatkin, J. P. (2015). Child & adolescent mental health: A practical, all-in-one guide. New York:  W. W. Norton & Company.

 

Stentebjerg-Olesen, M., Pagsberg, A. K., Fink-Jensen, A., Correll, C. U., & Jeppesen, P. (2016). Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in children and adolescents: A systematic review. Journal of Child and Adolescent Psychopharmacology, 26(5), 410-427.

 

 

Dannie S. Harris
WKPIC Doctoral Intern